Damora Therapeutics (NASDAQ: DMRA) granted inducement equity awards to six newly hired non-executive employees on June 1, 2026 under Nasdaq Listing Rule 5635(c)(4).
The grants are non-qualified stock options for an aggregate 372,000 shares at a $24.88 exercise price, with a 10-year term and four-year vesting schedule.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
None.
Negative
None.
Key Figures
Option grant size:372,000 sharesExercise price:$24.88 per shareOption term:10 years+3 more
6 metrics
Option grant size372,000 sharesAggregate non-qualified options in June 1, 2026 inducement grants
Exercise price$24.88 per shareExercise price for inducement stock options
Option term10 yearsTerm of non-qualified stock options in inducement grants
Large net loss driven by acquired in-process R&D charge and higher expenses.
Pattern Detected
Shares have reacted strongly to leadership changes and major financial updates, while routine inducement grant announcements have seen modest or negative moves.
Recent Company History
Over recent months, Damora reported full-year 2025 and Q1 2026 results, highlighting cash of about $535M–$532.9M and net losses driven by R&D investment and acquired in-process R&D. Management changes, including appointing Jennifer Jarrett as CEO effective March 30, 2026, coincided with a 27.07% move. The company has repeatedly used Nasdaq Listing Rule 5635(c)(4) for inducement grants, similar in structure to today’s announcement.
Market Pulse Summary
This announcement details standard inducement equity awards for six new non-executive hires, totalin...
Analysis
This announcement details standard inducement equity awards for six new non-executive hires, totaling 372,000 non-qualified options at an exercise price of $24.88 and a 10-year term, vesting over four years. It continues Damora’s established use of Nasdaq Listing Rule 5635(c)(4) seen in prior months. Investors may track how ongoing hiring, leadership changes, and earlier cash runway disclosures support execution of programs like DMR-001, DMR-002, and DMR-003.
"The inducement grants were approved ... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement grantsfinancial
"today announced that it granted equity awards ... The inducement grants were approved..."
Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.
non-qualified stock optionsfinancial
"The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares..."
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on June 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants consist of non-qualified stock options to purchase an aggregate of 372,000 shares of Damora’s common stock with a 10-year term and an exercise price of $24.88 per share. All of the options vest as to 25% on the first anniversary of the employees’ start date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of a non-qualified stock option award agreement.
About Damora Therapeutics
Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit www.damoratx.com or follow us on LinkedIn.
What inducement grants did Damora Therapeutics (DMRA) announce on June 1, 2026?
Damora Therapeutics announced non-qualified stock option inducement grants covering 372,000 shares for six newly hired non-executive employees. According to Damora, these options were approved by the independent Compensation Committee as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).
What is the exercise price and term of the new Damora Therapeutics (DMRA) inducement stock options?
The newly granted Damora Therapeutics inducement stock options have a $24.88 per share exercise price and a 10-year term. According to Damora, these non-qualified stock options cover an aggregate of 372,000 shares of common stock for six newly hired non-executive employees.
How do the Damora Therapeutics (DMRA) inducement grants vest for the six new employees?
The Damora Therapeutics inducement options vest 25% on the first employment anniversary, then monthly over 36 months. According to Damora, this four-year vesting schedule applies to all 372,000 non-qualified stock options granted under its 2022 Inducement Plan and related award agreements.
Under which plan were the Damora Therapeutics (DMRA) inducement options granted in June 2026?
The June 2026 inducement options were granted under the 2022 Damora Therapeutics Inducement Plan. According to Damora, the non-qualified stock option awards are also governed by a non-qualified stock option award agreement, outlining additional terms and conditions for the 372,000 granted options.
Why were the June 1, 2026 Damora Therapeutics (DMRA) stock options classified as inducement grants?
The June 1, 2026 stock options were classified as inducement grants to encourage acceptance of employment. According to Damora, the independent Compensation Committee approved these non-qualified options in line with Nasdaq Listing Rule 5635(c)(4) for six newly hired non-executive employees.
